Shares of Fortress Biotech Inc. (FBIO) are rising over 17% in pre-market today, after the company announced that its partner company Oncogenuity Inc. has entered into an exclusive worldwide licensing agreement with Columbia University to develop novel oligonucleotides for the treatment of genetically driven cancers.
from RTT - Before the Bell https://ift.tt/2SKE8uG
via IFTTT
No comments:
Post a Comment